Senior Director, Real World Data & Analytics

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, Real-World Data & Analytics will work with the Executive Director, Head of Epidemiology and VP of HEOR to establish the RWD&A group at RevMed, scaling organizational capabilities and leading the strategy and execution of key RWD&A deliverables for RevMed assets. They will be accountable for working across the clinical development, safety, medical affairs, commercial including analytics and insights, and IT matrix, developing strategies and leading and/or overseeing execution of key projects. Reporting to the Executive Director, Head of Epidemiology & RWD Strategy, they will closely align with the other users of RWD at RevMed, develop ways of working and communication channels to maximize RevMed’s investment in RWD as well as lead the analysis (either directly or leveraging junior team members and vendors) of RWD database and other studies. This is an exceptional opportunity to contribute to the advancement of oncology by leveraging real-world data and analytics that will shape the future of patient care. Develop and lead RWD and analytics plans to support portfolio, Medical Affairs, HEOR/RWE, and epidemiology goals. Provide subject matter expertise on RWD data sources, their strengths/limitations, and the feasibility of answering key scientific questions using available data. Oversee high-quality RWE study design, protocol development, statistical analysis planning, and final reporting in support of regulatory submissions and product value evidence – typical projects include include systematic literature reviews, natural history studies, clinical trial design and optimization, comparative effectiveness and safety, and healthcare resource utilization types of studies, post-approval safety studies leveraging RWD, as well as RWD-related insights such as quick feasibility and information used to inform our fast-moving clinical programs. Ensure fit-for-purpose methods are used to provide scientific rigor to non-interventional studies so that they adhere to global regulatory guidance frameworks and are acceptable to other key stakeholders. Provide thought leadership in advanced analytic techniques (e.g., causal inference, predictive modeling, AI/ML) that reflect current industry practices. Communicate insights and analysis effectively to senior stakeholders, regulatory agencies, payers, and scientific audiences through written reports and presentations. Participate in governance, feasibility review, and multidisciplinary project teams, ensuring RWD analytics add meaningful insight at key decision points. Build, mentor, and lead a high-performing analytics team with expertise in epidemiology, biostatistics, data science, and RWE methodologies. Drive adoption of robust analytics standards and tools that enhance consistency and scalability of RWD efforts across projects including partnership with other functions to establish data ingestion pipelines, and support the establishment of data lakes. Required Skills, Experience and Education: PhD / DSc / DrPH in epidemiology or biostatistics, or a relevant advanced science degree and at least 12 years of experience with RWD analytics and evidence generation in pharma/biotech. Demonstrated experience leading c